|
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
The NTRK1 gene in the q arm of chromosome 1 encodes one of the receptors for the nerve growth factor and is frequently activated as an oncogene in papillary thyroid carcinomas.
|
9172002 |
1997 |
|
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we have analyzed by different molecular approaches, including Southern blotting, DNA transfection assay on NIH-3T3 cells, and reverse transcription-PCR analysis, six papillary carcinomas from children living in the region of Belarus at the time of the Chernobyl nuclear accident to identify tumor-specific gene rearrangements of the proto-oncogenes RET and TRK, previously found activated in a tumor type-specific manner in papillary thyroid carcinoma.
|
7585643 |
1995 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results concerning the radiation-associated tumours showed that only rearrangements between NTRK1 and TPM3 genes (TRK oncogene) were detected in 2/14 papillary carcinomas and in one lymph-node metastasis of one of these papillary thyroid carcinomas.
|
10646882 |
2000 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high prevalence of RET gene rearrangements (62.3%) with a significant predominance of ELE1/RET (PTC3) over H4/RET (PTC1) rearrangements was found in PTCs of the first post-Chernobyl decade.NTRK1 rearrangements were rare (3.3%).
|
10741739 |
2000 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The former group did not differ from the wild-type group in terms of MTC size, prevalence of C-cell hyperplasia (CCH) or papillary thyroid carcinoma (PTC).
|
18331611 |
2008 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer.
|
29606586 |
2018 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rearrangements of the RET and TRK proto-oncogenes, which generate fusion oncogenes, are frequent in papillary thyroid carcinomas in Caucasian populations.
|
10083732 |
1999 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because of similarities in involvement of the two tyrosine kinases RET (rearranged during transfection) and NTRK1 in the pathogenesis of PTC, the obvious parallels between RET and NTRK1 and between PTC and medullary thyroid carcinoma (MTC), NTRK1 seemed to be an excellent candidate gene to play a role in the genesis of MTC.
|
10443680 |
1999 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, several gene products with unknown functions were demonstrated in PTCs bearing RET or NTRK1 hybrids versus rearrangement-negative PTCs, including a homologue of the Ig kappa light chain constant region.
|
16256137 |
2006 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For example, ret and trk genes were found to be activated by gene rearrangements in human papillary thyroid carcinomas.
|
1486840 |
1992 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages.
|
11165748 |
2001 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seven of 27 PTCs (26%) had neurotrophic tyrosine kinase receptor (NTRK) fusion oncogenes (NTRK type 3/ets variant 6 [NTRK3/ETV6], n =5; NTRK3/unknown, n = 1; and NTRK type 1/translocated promoter region, nuclear basket protein [NTRK1/TPR], n = 1), including 5 tumors that measured >2 cm and 3 that diffusely involved the entire thyroid or lobe.
|
26784937 |
2016 |
|
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
|
19883730 |
2010 |
|
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
The TFG sequence is fused to the 3' end of NTRK1, generating the TRK-T3 fusion transcript found in papillary thyroid carcinoma.
|
9169129 |
1997 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of the oncogene BRAF or rearrangements of the tyrosine kinase receptor RET are observed in up to 80% of papillary thyroid carcinomas (PTCs).
|
20652698 |
2010 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The TPM3 gene has been previously found in papillary thyroid carcinomas as a fusion partner with the TRK kinase gene.
|
10216106 |
1999 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results show that, in papillary thyroid carcinoma, the frequency of RET and NTRK1 activation is significantly higher in the group of patients aged 4-30 years, thas supporting the concept that age could be contributing to this thyroid specific carcinogenic process.
|
8626874 |
1996 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These structural changes lead to the formation of fusion genes RET-PTC, TRK(-T), and BRAF-AKAP9, which originate as a result of intrachromosomal or interchromosomal rearrangements and are found in papillary thyroid carcinoma.
|
20951315 |
2010 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident.
|
10074915 |
1999 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
|
19883730 |
2010 |
|
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The high incidence of yet uncharacterized NTRK1 hybrid mRNAs in our patient cohort leads to the speculation that activating chromosomal rearrangements of several tyrosine kinase receptors may be a common feature of PTCs and that the expression of distinct chimeras may potentially be of prognostic significance.
|
11114633 |
2000 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We exploited the MassARRAY (MA) genotyping platform to develop the "PTC-MA assay", which allows the simultaneous detection of 13 hotspot mutations, in the BRAF, KRAS, NRAS, HRAS, TERT, AKT1, PIK3CA, and EIF1AX genes, and six recurrent genetic rearrangements, involving the RET and TRK genes in papillary thyroid cancer (PTC).
|
29214440 |
2018 |
|
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.
|
30664823 |
2019 |
|
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight PTCs expressed two different mutations (1 RET/PTC + BRAF, 6 NTRK1 + BRAF, 1 RET/PTC + NTRK1).
|
20640859 |
2010 |